| Multiple Sclerosis, Secondary Progressive
Briumvi vs Aubagio
Side-by-side clinical, coverage, and cost comparison for multiple sclerosis, secondary progressive.Deep comparison between: Briumvi vs Aubagio with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsAubagio has a higher rate of injection site reactions vs Briumvi based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Aubagio but not Briumvi, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Briumvi
Aubagio
At A Glance
IV infusion
Every 24 weeks
Anti-CD20 monoclonal antibody
Oral
Daily
Pyrimidine synthesis inhibitor
Indications
- Multiple Sclerosis, Relapsing-Remitting
- Clinically isolated syndrome
- Multiple Sclerosis, Secondary Progressive
- Multiple Sclerosis, Secondary Progressive
- Clinically isolated syndrome
Dosing
Multiple Sclerosis, Relapsing-Remitting; Clinically isolated syndrome; Multiple Sclerosis, Secondary Progressive 150 mg IV infusion (first infusion), followed by 450 mg IV infusion 2 weeks later, then 450 mg IV every 24 weeks; pre-medicate with methylprednisolone (or equivalent corticosteroid) and antihistamine before each infusion.
Multiple Sclerosis, Secondary Progressive, Clinically isolated syndrome 7 mg or 14 mg orally once daily; may be taken with or without food.
Contraindications
- Active HBV infection
- History of life-threatening infusion reaction to ublituximab-xiiy
- Severe hepatic impairment
- Pregnancy or females of reproductive potential not using effective contraception
- History of hypersensitivity reaction to teriflunomide, leflunomide, or any inactive ingredient (including anaphylaxis, angioedema, or serious skin reactions)
- Coadministration with leflunomide
Adverse Reactions
Most common (>=10%) Infusion reactions, upper respiratory tract infections
Serious Infusion reactions, infections, reduction in immunoglobulins, liver injury
Postmarketing Liver injury, progressive multifocal leukoencephalopathy
Most common (>=2% above placebo) Headache, increased alanine aminotransferase, diarrhea, alopecia, nausea, paresthesia, arthralgia, neutropenia, hypertension
Serious Hepatotoxicity, bone marrow effects/immunosuppression/infections, hypersensitivity reactions, serious skin reactions, DRESS, cutaneous or mucocutaneous ulcers and impaired wound healing, peripheral neuropathy, increased blood pressure, respiratory effects, pancreatitis (pediatric patients)
Postmarketing Thrombocytopenia, pancreatitis, colitis, drug-induced liver injury, anaphylaxis, angioedema, interstitial lung disease, toxic epidermal necrolysis, Stevens-Johnson syndrome, DRESS, psoriasis (including pustular and nail), nail disorders, cutaneous or mucocutaneous ulcers, impaired wound healing
Pharmacology
Anti-CD20 chimeric monoclonal IgG1 antibody with reduced fucose content; binds CD20 on pre-B and mature B lymphocytes and causes cell lysis via antibody-dependent cellular cytolysis and complement-dependent cytolysis.
Teriflunomide is an immunomodulatory agent with anti-inflammatory properties that inhibits dihydroorotate dehydrogenase, a mitochondrial enzyme required for de novo pyrimidine synthesis, which may reduce the number of activated lymphocytes in the CNS.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Briumvi
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (9/12) · Qty limit (9/12)
Aubagio
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (4/12)
UnitedHealthcare
Briumvi
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Aubagio
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (1/8)
Humana
Briumvi
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (0/3)
Aubagio
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAccessia Health: Multiple Sclerosis - Private Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAccessia Health: Multiple Sclerosis - Private Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
BriumviView full Briumvi profile
AubagioView full Aubagio profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.